• Analysts' Weekly Ratings Updates for Neurocrine Biosciences

    19 days ago - By ETF Daily News

    Neurocrine Biosciences recently received a number of ratings updates from brokerages and research firms:
    12/8/2021 - Neurocrine Biosciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $140.00 to $154.00. They now have an “outperform” rating on the stock.
    12/8/2021 - Neurocrine Biosciences was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory...
    Read more ...

     

  • Investment Analysts' Weekly Ratings Changes for Oshkosh

    Investment Analysts' Weekly Ratings Changes for Oshkosh

    19 days ago - By ETF Daily News

    Oshkosh recently received a number of ratings updates from brokerages and research firms:
    12/20/2021 - Oshkosh had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $128.00 to $127.00. They now have a “buy” rating on the stock.
    12/17/2021 - Oshkosh is now covered by analysts at DA Davidson. They set a “neutral” rating and a $118.00 price target on the stock.
    12/10/2021 - Oshkosh had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $124.00 to $128.00. They now have a “buy” rating on the stock.
    12/9/2021 - Oshkosh had its price target...
    Read more ...